MTOR and metastatic malignant neoplasm: Importantly, early treatment with a PI3K/mTOR inhibitor (dactolisib) prevented the UBE2C-induced leptomeningeal dissemination in these models, revealing a promising therapeutic avenue in advanced metastatic cancer prevention.